Business Wire

Taktile Unveils AI Agents Enabling Banks to Process 5x More SMB Loans Without Extra Headcount

10.9.2025 14:00:00 CEST | Business Wire | Press Release

Share

Taktile, the AI Decision Platform for financial services, today announced the launch of its fully customizable AI agents, a capability designed to transform how financial institutions perform credit underwriting.

For years, underwriting teams have been constrained by manual document reviews, scattered data, and growing backlogs. With Taktile’s customizable AI agents, SMB lenders can now process 5x more loans without adding headcount – eliminating bottlenecks and freeing underwriters to focus on high-value, strategic decisions.

“Credit teams don’t need another AI tool that adds complexity – they need a workforce multiplier,” said Maximilian Eber, Co-Founder and CPTO of Taktile. “With Taktile’s customizable AI agents, teams can automate the repetitive tasks that overwhelm them, while maintaining the accuracy, transparency, and human oversight required in financial services. What makes this truly different is that these agents are not one-size-fits-all – they are fully customizable blueprints. Teams can adapt them instantly to their own strategy and deploy updates in minutes, without engineering support.”

Each AI agent is designed to work seamlessly alongside human underwriters, orchestrating specialist tasks that previously took hours of manual effort, for example:

  • Document parsing: Extracting key data points from unstructured documents and turning them into structured, decision-ready inputs.
  • Web verification: Confirming business websites, validating models, and surfacing red flags from the open web.
  • Financial analysis: Reviewing statements, assessing risk, suggesting pricing, and generating ready-to-use decision summaries.

Unlike generic AI pilots that often stall before reaching production, Taktile’s AI agents are production-ready, instantly adaptable, and deployable in weeks. Teams decide how much to automate and when underwriters should step in, blending AI workflows with rules-based logic where appropriate.

The launch also integrates directly with Taktile’s Data Marketplace, enabling institutions to extend their AI agents with best-in-class third-party data providers. Teams can test changes, instantly see the impact on decision outcomes, and push updates live immediately – avoiding the technology bottlenecks that slow most AI initiatives.

“This is the future of underwriting,” added Eber. “Automated, accurate, customizable – and entirely in your control.”

To learn more, visit: https://taktile.com/ai-agents-smb-lending

About Taktile

Taktile is an AI Decision Platform that helps financial institutions automate and improve their risk management strategies across the entire customer lifecycle. From onboarding and credit underwriting to fraud detection and transaction monitoring, Taktile empowers risk teams to build, test, and optimize their critical decision processes, without relying on engineers. Taktile has been recognized as category leader — for four quarters in a row — in G2’s Quarterly Report for Decision Management Platforms, and is trusted by leading fintechs, banks, and insurers across the globe. The company is headquartered in New York City and has offices in Berlin and London. For more information, visit taktile.com or follow Taktile on LinkedIn.

View source version on businesswire.com: https://www.businesswire.com/news/home/20250910730509/en/

Contacts

ashley.baird@taktile.com

(c) 2024 Business Wire, Inc., All rights reserved.

Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

BeOne Presents Compelling Data in Hard-to-Treat Liver and Lung Cancers at ESMO 202624.10.2026 10:15:00 CEST | Press Release

BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new data from multiple differentiated investigational medicines across its priority solid tumor disease areas at the European Society for Medical Oncology (ESMO) Congress 2026 (October 23–27, Madrid). The presentations span gastrointestinal, lung, and breast cancers, and reflect the growing momentum of BeOne’s solid tumor franchise. Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne, said: “At ESMO, we are showing how our strategy of matching the right modality to disease biology is translating into meaningful clinical progress. Our GPC3 x 4-1BB bispecific antibody continues to be well tolerated and demonstrates durable activity with longer follow up in patients with heavily pre-treated hepatocellular carcinoma, while the first clinical data from our brain-penetrant PRMT5 inhibitor and CEA-targeting ADC expand our innovation in non-small cell lung cancer. Alongsi

Phase 3 RAINIER Results Supporting Best-in-Class Potential of Povetacicept in IgA Nephropathy Published in the New England Journal of Medicine and Presented at the American Society of Nephrology Kidney Week 202623.10.2026 19:42:00 CEST | Press Release

Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the publication of Phase 3 RAINIER results for povetacicept in the New England Journal of Medicine (NEJM), presentation of these data at the American Society of Nephrology (ASN) Kidney Week 2026 in Denver, Colorado, and advancement of the povetacicept clinical research program in IgAN. Vertex will also host an investor event during ASN on October 23 at 6:15-7 p.m. MDT (8:15-9 p.m. EDT). Further details are below. Data being presented include a pre-specified Week 36 interim analysis of the ongoing Phase 3 RAINIER trial of povetacicept, an engineered fusion protein and dual inhibitor of the BAFF (B cell activating factor) and APRIL (a proliferation inducing ligand) cytokines, in immunoglobulin A nephropathy (IgAN). RAINIER met its primary endpoint, with povetacicept achieving a 52.0% reduction from baseline in proteinuria at Week 36 and a statistically significant and clinically meaningful 49.8% reduction versus placebo (

Lifezone Metals Confirms Advanced Negotiations with Orion CMC on Kabanga Nickel Project23.10.2026 16:19:00 CEST | Press Release

Lifezone Metals Limited (NYSE: LZM) notes comments made today by Oskar Lewnowski, Founder and Group Chief Executive of Orion Resource Partners, in an interview with Bloomberg Television regarding the Company’s Kabanga Nickel Project in Tanzania. In response to inbound inquiries from media outlets and investors following the interview, the Company can confirm that negotiations with Orion Critical Mineral Consortium (Orion CMC) regarding a significant equity investment into the Kabanga Nickel Project are at an advanced stage. The Orion CMC is a global investment platform launched by Orion Resource Partners in partnership with the U.S. International Development Finance Corporation (DFC) and Abu Dhabi's sovereign investor ADQ. As previously announced, the Company has been running a competitive process, led by Standard Chartered Bank, to secure a strategic investment into the Kabanga Nickel Project. Social Media LinkedIn | X | YouTube About Lifezone Metals Lifezone Metals (NYSE: LZM) is com

BeOne Medicines Reports Sustained Survival Benefit with TEVIMBRA-ZIIHERA Combination in First-Line HER2+ Gastroesophageal Cancer23.10.2026 16:15:00 CEST | Press Release

BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new survival results from the planned second interim analysis (IA2) and final formal analysis of the Phase 3 HERIZON-GEA-01 trial, further confirming the benefit of TEVIMBRA® (tislelizumab) plus ZIIHERA® (zanidatamab) and chemotherapy as first-line treatment for patients with HER2-positive locally advanced or metastatic gastroesophageal adenocarcinoma (GEA). The results will be presented today as a late-breaking abstract during a rapid oral session at the European Society for Medical Oncology (ESMO) Congress 2026 in Madrid, Spain (LBA79). Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne, said: “Following the U.S. approval in August, these longer-term data provide further evidence supporting TEVIMBRA plus ZIIHERA and chemotherapy as the new standard of care in all first-line HER2-positive advanced gastroesophageal adenocarcinoma patients, regardless of PD-L1 sta

inDrive and Pony.ai Announce Collaboration to Explore Autonomous Mobility in Kazakhstan Built on NVIDIA Hyperion23.10.2026 15:00:00 CEST | Press Release

inDrive, the global mobility and delivery platform, today announced it has signed a memorandum of understanding (MOU) with NVIDIA and Pony.ai, a global leader in the large-scale commercialization of autonomous driving technology, to explore the future of autonomous ride-hailing. Kazakhstan will serve as the first test market. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261023143469/en/ inDrive partners with Pony.ai and NVIDIA to explore autonomous mobility in Kazakhstan Kazakhstan was chosen first for its regulatory readiness following the creation of the country’s first structured legal framework for driverless transport, as part of its “Year of Digitalization and Artificial Intelligence.” Combined with Kazakhstan’s position as a leading Central Asian economy, this gives the companies a clear basis to assess autonomous ride-hailing in practice. The three companies will evaluate the technical, operational, regulatory and

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye